The market, valued at USD 204.31 billion in 2025, is projected to grow at a 6.69% CAGR, with major players including Abbott, Sun Pharma, Dr. Reddy’s, and Cipla.
Growth is fueled by rising demand for affordable branded medicines, patent expiries, and new product launches, especially in cardiovascular and anti-diabetic segments. North America leads, with Asia Pacific and Europe showing strong expansion.
Intense price competition from unbranded generics, regulatory challenges, and quality compliance issues pose risks. Strategic partnerships and differentiated branding are helping companies maintain market share amid growing chronic disease burdens worldwide.
With new US drug pricing policies, how will global manufacturers adjust their strategies?
As blockbuster drugs lose patents, which companies are poised to win the race?
Why are companies seemingly ignoring a $189 billion opportunity in biosimilar drugs?
Could the rise of branded generics actually be slowing down healthcare cost reduction?
Is the premium for branded generics a price for quality or just marketing?
Why is China's bulk-buying policy seen as a major threat to global drug profits?